BMS-986504 for Peripheral Nerve Sheath Tumor

Overseen By Ankit Mangla, MD

Age: Any Age

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Ankit Mangla, MD

Must not be taking: CYP3A4 inhibitors, CYP3A4 inducers, PPIs, others

Disqualifiers: PRMT5 inhibitor, Gastrointestinal disease, Active drug use, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 2 years

What You Need to Know Before You Apply

What is the purpose of this trial?

People who have a cancer called MPNST, or Malignant Peripheral Nerve Sheath Tumor, may be eligible for this study. The purpose of this study is to see if a new medicine called BMS-986504 may work better than other available medicines for people with MPNST. Methylthioadenosine Phosphorylase (MTAP) loss is a gene mutation that some people have. MTAP loss seems to increase the chance that BMS-986504 can kill MPNST cancer cells. People who are missing MTAP from their tumor may be able to enroll in this study. Treating MPNST based on MTAP loss is considered experimental and is not approved by the US Food and Drug Administration (FDA) for determining whether BMS-98650 will be active against cancer. The purpose of this study is to evaluate the safety and effectiveness of BMS-986504 in participants with MPNST.

Who Is on the Research Team?

Ankit Mangla, MD

Principal Investigator

Case Comprehensive Cancer Center, University Hospitals

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 12 years old or older.

I am able and willing to sign consent forms for this study.

Pathohistological verification of MPNST

Exclusion Criteria

I have been treated with a PRMT5 inhibitor before.

Participants with active drug use

I am unable to swallow tablets.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BMS-986504 on Days 1-28 of each cycle until disease progression, unacceptable toxicity, or withdrawal of consent

Up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days post-treatment discontinuation

What Are the Treatments Tested in This Trial?

Interventions

• BMS-986504

How Is the Trial Designed?

Group I: BMS-986504 Experimental Treatment 1 Intervention

Participants will receive BMS-986504 on Days 1-28 of each cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent.

Who Is Running the Clinical Trial?

Ankit Mangla, MD

Lead Sponsor